BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson’s disease. As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
Through this collaboration, Indivi will take over the digital management of KonectomTM in the Phase 2b LUMA study evaluating the efficacy and safety of BIIB122 in participants with early-stage Parkinson’s disease, which is being developed in collaboration with Denali Therapeutics Inc. As part of this, Indivi will ensure the continued deployment of KonectomTM including ongoing service availability, development, maintenance, algorithm development and data processing to generate derived digital measures from the LUMA study. In addition, Biogen and Indivi aim to develop and validate novel digital endpoints in Parkinson’s disease as well as explore additional disease areas for endpoint development leveraging KonectomTM.
Guilhem Dupont, CEO of Indivi, says: “Through this multi-year strategic collaboration with Biogen, we aim to expand the reach of our unique technology to a new critical disease area where innovation is crucially needed and that may cross-fertilize with the progress of our scientific efforts in Multiple Sclerosis. This collaboration is a testament to the hard work and dedication of our entire team over the past 5 years in developing transformative digital measurements to support research in neuroscience, and we are committed to continue building on this success.”
To date no disease-modifying treatments for Parkinson’s have been developed and those efforts have been hampered by current subjective clinical measurement instruments. Indivi uses advanced computational and statistical modelling methods to potentially yield more precise measures of progression of Parkinson’s disease with improved signal-to-noise properties. By bringing KonectomTM together with dreaMSMD, a digital biomarker platform for people with multiple sclerosis, Indivi will be able to offer a best-in-class digital measurement technology solution that will comprehensively cover all key areas of interest in neurology.
About Indivi
Indivi is a leading Medtech for the development of digital biomarkers in neuroscience, based in Basel, Switzerland. Indivi is committed to developing and validating novel digital endpoints in neuro-degenerative diseases (multiple sclerosis, Parkinson’s and Alzheimer’s diseases). Indivi is dedicated to unlocking the immense potential of digital biomarkers in drug development and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence). Through end-to-end joint development endeavours with biotech & pharmaceutical companies, Indivi is poised to continue its growth and success in the nascent digital biomarker industry and lead the field of science in digital measurements for neuroscience R&D.
Contacts
For more information:
Guilhem Dupont, CEO, guilhem.dupont@Indivi.io